Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.   

artificial intelligence robot evaluates healthcare data

Novo Nordisk spends $60M on advanced AI in search of new cardiovascular medications

Novo Nordisk is working with Valo Health to identify potential new treatments for cardiometabolic conditions. If it proves to be a fruitful collaboration, the initial payment of $60 million will be just the beginning. 

Warfarin after TAVR is safe, but fails to boost outcomes

Researchers examined two-year data from transfemoral TAVR patients treated with low-dose aspirin and 30 days of warfarin or just aspirin on its own. 

Thumbnail

FDA approves empagliflozin for treating chronic kidney disease

The popular SGLT2 inhibitor, sold by Boehringer Ingelheim and Eli Lilly and Company under the name Jardiance, has already been approved by the FDA to treat type 2 diabetes and heart failure.

Thumbnail

NOACs vs. VKAs in TAVR patients with new-onset AFib: New meta-analysis examines key differences

The biggest differences between the two treatment options were major bleeding events and all-cause mortality. There was no significant difference when it came to stroke risk. 

Thumbnail

Long-term cannabis use may not increase heart attack risk, new study finds—but many questions remain

Access to cannabis is skyrocketing across the United States, but much more research is still needed on its long-term side effects. 

Thumbnail

Low-cost generic programs offer CVD medications at affordable prices—but availability changes from one to the next

Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. 

money maze payment reimbursement

Weight loss drug semaglutide linked to better heart health, but high costs may limit its impact

It could cost more than $1 million just to avoid a single heart attack, stroke or cardiovascular death, researchers wrote. 

the words "FDA recall" on a board

Seeds for weight loss recalled: FDA says they are a ‘highly toxic’ plant containing cardiac glycosides

The FDA found that the seeds are actually yellow oleander, a poisonous plant known to contain cardiac glycosides.